Table 3. Stratified BP control rates (ESH/ESC 2013:<140/85 mm Hg for diabetes patients in each treatment group and 140/90 mm Hg for all other patients, n/N (%) at week 8 in high-risk and non-high-risk individuals treated with nifedipine GITS (N20, 30, 60) and/or candesartan cilexetil (C4, 8, 16, 32) or placebo (efficacy analysis set).
| Treatment group |
Renal impairment of any grade (baseline eGFR<90 ml min−1) |
T2DM |
Hypercholesterolaemia (total cholesterol>240 mg dl−1) |
CV risk factor(s) (T2DM or BMI⩾30 kg m−2
or LDL⩾130 mg dl−1) |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Yes (N=422) | No (N=940) | Yes (N=202) | No (N=1160) | >240 (N=206) | 200–240 (N=450) | <200 (N=704) | 1–3 (N=971) | 1–2 (N=943) | 1 (N=669) | None (N=391) | |
| Placebo | 3/27 (11.1%) | 4/59 (6.8%) | 2/13 (15.4%) | 5/73 (6.8%) | 0/14 | 2/28 (7.1%) | 5/44 (11.4%) | 5/68 (7.4%) | 5/67 (7.5%) | 3/46 (6.5%) | 2/18 (11.1%) |
| C4 | 5/23 (21.7%) | 17/61 (27.9%) | 4/15 (26.7%) | 12/69 (17.4%) | 3/9 (33.3%) | 6/24 (25.0%) | 13/51 (25.5%) | 16/59 (27.1%) | 15/56 (26.8%) | 9/36 (25.0%) | 6/25 (24.0%) |
| C8 | 10/29 (34.5%) | 28/58 (48.3%) | 4/13 (30.8%) | 18/74 (24.3%) | 6/11 (54.5%) | 15/31 (48.4%) | 16/44 (36.4%) | 27/63 (42.9%) | 27/62 (43.5%) | 18/43 (41.9%) | 11/24 (45.8%) |
| C16 | 13/35 (37.1%) | 11/49 (22.4%) | 2/13 (15.4%) | 19/71 (26.8%) | 7/18 (38.9%) | 4/20 (20.0%) | 13/46 (28.3%) | 14/55 (25.5%) | 13/53 (24.5%) | 10/37 (27.0%) | 10/29 (34.5%) |
| C32 | 11/28 (39.3%) | 28/56 (50.0%) | 3/10 (30.0%) | 23/74 (31.1%) | 4/12 (33.3%) | 16/28 (57.1%) | 18/43 (41.9%) | 26/64 (40.6%) | 26/63 (41.3%) | 18/42 (42.9%) | 13/20 (65.0%) |
| N20 | 7/27 (25.9%) | 16/58 (27.6%) | 3/10 (30.0%) | 14/75 (18.7%) | 1/13 (7.7%) | 10/30 (33.3%) | 12/42 (28.6%) | 17/57 (29.8%) | 17/56 (30.4%) | 13/41 (31.7%) | 6/28 (21.4%) |
| N30 | 8/30 (26.7%) | 18/53 (34.0%) | 3/16 (18.8%) | 14/67 (20.9%) | 5/17 (29.4%) | 9/27 (33.3%) | 12/39 (30.8%) | 21/63 (33.3%) | 21/60 (35.0%) | 15/44 (34.1%) | 5/20 (25.0%) |
| N60 | 11/29 (37.9%) | 20/51 (39.2%) | 5/16 (31.3%) | 20/64 (31.3%) | 2/12 (16.7%) | 9/25 (36.0%) | 20/43 (46.5%) | 22/59 (37.3%) | 21/54 (38.9%) | 18/44 (40.9%) | 9/21 (42.9%) |
| N20C4 | 15/28 (53.6%) | 23/59 (39.0%) | 2/8 (25.0%) | 27/79 (34.2%) | 8/15 (53.3%) | 9/23 (39.1%) | 21/49 (42.9%) | 27/62 (43.5%) | 27/61 (44.3%) | 20/44 (45.5%) | 11/25 (44.0%) |
| N20C8 | 11/18 (61.1%) | 37/70 (52.9%) | 6/14 (42.9%) | 31/74 (41.9%) | 8/13 (61.5%) | 15/31 (48.4%) | 25/44 (56.8%) | 35/67 (52.2%) | 33/64 (51.6%) | 24/44 (54.5%) | 13/21 (61.9%) |
| N20C16 | 16/27 (59.3%) | 34/60 (56.7%) | 7/17 (41.2%) | 30/70 (42.9%) | 7/12 (58.3%) | 16/29 (55.2%) | 27/46 (58.7%) | 34/66 (51.5%) | 33/65 (50.8%) | 23/43 (53.5%) | 16/21 (76.2%) |
| N30C8 | 16/31 (51.6%) | 26/55 (47.3%) | 3/8 (37.5%) | 32/78 (41.0%) | 9/13 (69.2%) | 15/25 (60.0%) | 18/48 (37.5%) | 31/61 (50.8%) | 30/60 (50.0%) | 19/40 (47.5%) | 11/25 (44.0%) |
| N30C16 | 16/22 (72.7%) | 33/66 (50.0%) | 5/13 (38.5%) | 31/75 (41.3%) | 7/9 (77.8%) | 20/39 (51.3%) | 22/40 (55.0%) | 32/59 (54.2%) | 32/57 (56.1%) | 24/40 (60.0%) | 17/29 (58.6%) |
| N30C32 | 18/27 (66.7%) | 38/60 (63.3%) | 6/9 (66.7%) | 37/78 (47.4%) | 11/16 (68.8%) | 17/32 (53.1%) | 28/39 (71.8%) | 37/53 (69.8%) | 37/52 (71.2%) | 27/37 (73.0%) | 19/34 (55.9%) |
| N60C16 | 11/16 (68.8%) | 37/66 (56.1%) | 7/16 (43.8%) | 32/66 (48.5%) | 5/11 (45.5%) | 15/25 (60.0%) | 28/46 (60.9%) | 33/61 (54.1%) | 31/59 (52.5%) | 25/47 (53.2%) | 15/21 (71.4%) |
| N60C32 | 15/25 (60.0%) | 37/59 (62.7%) | 6/11 (54.5%) | 38/73 (52.1%) | 8/11 (72.7%) | 21/33 (63.6%) | 23/40 (57.5%) | 33/54 (61.1%) | 33/54 (61.1%) | 26/41 (63.4%) | 19/30 (63.3%) |
Abbreviations: BMI, body mass index; BP, blood pressure; C, candesartan cilexetil; CV, cardiovascular; eGFR, estimated glomerular filtration rate; LDL, low-density lipoprotein; N, nifedipine GITS; T2DM, type 2 diabetes mellitus.